Skip to main content

Opioid Related Disorder

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Indivior
IndiviorUK - Slough
2 programs
2
RBP-6000Phase 21 trial
RBP-6300Phase 21 trial
Active Trials
NCT01738503Completed124Est. May 2014
NCT01582347Completed143Est. Nov 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IndiviorRBP-6000
IndiviorRBP-6300

Clinical Trials (2)

Total enrollment: 267 patients across 2 trials

Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

Start: Oct 2012Est. completion: May 2014124 patients
Phase 2Completed

Transfer of Subjects From Subutex/Suboxone to RBP-6300

Start: Mar 2012Est. completion: Nov 2012143 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.